TY - THES A1 - Weiß, Matthias T1 - Die Bedeutung nosokomialer Infektionen bei der Therapie von chirurgischen und anästhesiologischen Intensivpatienten T1 - The significance of hospital acquired infections in the therapy of surgical and medical ICU-patients N2 - Beobachtung nosokomialer Infektionen bei intensivhospitalisierten Patienten im Rahmen einer einjährigen prospektiven, multizentrischen Kohortenstudie. Besondere Beachtung von Komplikationen wie Sepsis und Peritonitis sowie des Auftretens multiresistenter Keime bei der Infektentstehung. N2 - Surveillance of nosocomial ICU-acquired infections in intensive care unit patients in a 1-year prospective multicenter cohort study. Monitoring of complications like sepsis and peritonitis and acquisition of multi-resistant infectious agents. KW - Sepsis KW - MRSA KW - Bauchfellentzündung KW - Hygiene KW - Allgemeine Entzündungsreaktion KW - Lungenentzündung KW - Sekundärkrankheit KW - Multimorbidität KW - Antibiose KW - Peritonitis KW - nosokomial KW - SIRS KW - Intensivstation KW - Komorbidität KW - ICU KW - HAI KW - mortality KW - SIRS KW - comorbidities Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-80565 ER - TY - THES A1 - Eisoldt, Stefan T1 - Additive Therapie der intraabdominellen Infektion - Ergebnisevaluierung einer deutschen Multicenterstudie T1 - Additive therapy of intraabdominell infections - Evaluation of a german multicentre study N2 - Diese multizentrische, randomisierte, doppel-blinde Studie hatte zum Ziel, die additive Wirksamkeit von Pentaglobin® bei der Behandlung der Peritonitis zu untersuchen. Pentaglobin® wurde hierbei zusammen mit einer im klinischen Alltag üblichen Antibiotikatherapie intravenös verabreicht. Die Kontrollgruppe erhielt ein Placebo bestehend aus Humanalbumin. Primäre Endpunkte waren der postoperative kumulierte Summenwert der SIRS-Kriterien nach Bone bis zum 23. postoperativen Tag sowie der postoperative kumulierte Summenwert des SOFA-Score bis zum 28. postoperativen Tag. Ergebnisse wurden durch Anwendung verschiedener Scores überprüft. Insgesamt konnten 260 Patienten mit Peritonitis an 16 Studienzentren eingeschlossen werden. 258 Patienten kamen in die Safety-Analyse sowie 255 in die Intentio-To-Treat Analyse. Bei den primären Endpunkten konnte eine Tendenz für die Wirksamkeit von Pentaglobin® bei septischen Patienten gezeigt werden. Insbesondere die Patienten mit einem höheren MPI-Wert scheinen mehr von einer Therapie mit Pentaglobin® profitiert zu haben. Eine statistische Signifikanz konnte jedoch nicht nachgewiesen werden. Bei den sekundären Endpunkten zeigte sich eine statistisch signifikant kürzere Therapie mit Katecholaminen in der Pentaglobin®-Gruppe. Weiterhin fanden sich statistisch signifikante Unterschiede des IL-2-Rezeptors sowie des TNF-1-Rezeptors im Studienverlauf zwischen der Pentaglobin®- und der Placebo-Gruppe. Bei der Überprüfung der Verträglichkeit der Studienmedikation fanden sich keine signifikanten Unterschiede. N2 - The aim of the present clinical trial was to show a therapeutic effect of Pentaglobin® under concomitant administration of antibiotics in patients with beginning peritoneal infections. The study was conducted as a placebo-controlled, double-blind, multicentre and prospective trial of clinical phase IV. The patients were allocated to the two treatment groups (Pentaglobin®/placebo) by randomisation. The primary efficacy parameters were the post-operative cumulative sum score of the SIRS criteria according to Bone until Day 23 and the post-operative cumulative Sequential Organ Failure Assessment (SOFA) sum score until Day 28. In total 260 patients with beginning intraabdominell infection in 16 study centres were included in the study. 258 patients were included in the safety analyses and 255 in the Intention-to-treat analyses. In conclusion, the efficacy results in this study showed a tendency in favour of Pentaglobin® compared to placebo regarding the primary efficacy parameters cumulative SIRS score and cumulative SOFA score that were lower in the Pentaglobin® group than in the placebo group, especially in patients with a more severe peritonitis. The differences between Pentaglobin® and placebo in SIRS and SOFA score were not statistically significant, but patients in the Pentaglobin® group had a lower mean TISS-28 score, a shorter duration of fever, a shorter duration of ICU treatment and artificial ventilation and the duration of treatment with catecholamines was significantly shorter in the Pentaglobin® group. Regarding laboratory parameters, the inflammatory parameters decreased more in the Pentaglobin® group than in the placebo group (with significant differences in favour of Pentaglobin® for IL-2R and TNF-R1) while the significant differences in favour of Pentaglobin® for IgM, IgA, IgG were mainly caused by the administration of the intravenous immunoglobulin preparation (with significant differences in favour of Pentaglobin® for IgM, IgA, IgG). The safety data showed that Pentaglobin® and placebo were equally safe and well tolerated. KW - Randomisierung KW - Kontrollierte klinische Studie KW - Bauchfellentzündung KW - Sepsis KW - Pentaglobin KW - multizentrisch KW - doppel-blind KW - placebo-kontrolliert KW - SOFA KW - SIRS KW - peritonitis KW - sepsis KW - pentaglobin KW - randomised double-blind study Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-24660 ER - TY - JOUR A1 - Asch, Silke A1 - Kaufmann, Tobias Peter A1 - Walter, Michaela A1 - Leistner, Marcus A1 - Danner, Bernd C. A1 - Perl, Thorsten A1 - Kutschka, Ingo A1 - Niehaus, Heidi T1 - The effect of perioperative hemadsorption in patients operated for acute infective endocarditis—A randomized controlled study JF - Artificial Organs N2 - Patients operated for infective endocarditis (IE) are at high risk of developing an excessive systemic hyperinflammatory state, resulting in systemic inflammatory response syndrome and septic shock. Hemoadsorption (HA) by cytokine adsorbers has been successfully applied to remove inflammatory mediators. This randomized controlled trial investigates the effect of perioperative HA therapy on inflammatory parameters and hemodynamic status in patients operated for IE. A total of 20 patients were randomly assigned to either HA therapy or the control group. HA therapy was initiated intraoperatively and continued for 24 hours postoperatively. Cytokine levels (IL‐6, IL‐1b, TNF‐α), leukocytes, C‐reactive protein (CRP), and Procalcitonin (PCT) as well as catecholamine support, and volume requirement were compared between both groups. Operative procedures included aortic (n = 7), mitral (n = 6), and multiple valve surgery (n = 7). All patients survived to discharge. No significant differences concerning median cytokine levels (IL‐6 and TNF‐α) were observed between both groups. CRP and PCT baseline levels were significantly higher in the HA group (59.5 vs. 26.3 mg/dL, P = .029 and 0.17 vs. 0.05 µg/L, P = .015) equalizing after surgery. Patients in the HA group required significantly higher doses of vasopressors (0.093 vs. 0.025 µg/kg/min norepinephrine, P = .029) at 12 hours postoperatively as well as significantly more overall volume replacement (7217 vs. 4185 mL at 12 hours, P = .015; 12 021 vs. 4850 mL at 48 hours, P = .015). HA therapy did neither result in a reduction of inflammatory parameters nor result in an improvement of hemodynamic parameters in patients operated for IE. For a more targeted use of HA therapy, appropriate selection criteria are required. KW - cytokines KW - endocarditis KW - hemadsorption KW - sepsis KW - SIRS Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262681 VL - 45 IS - 11 SP - 1328 EP - 1337 ER -